ReviewJournal of translational medicine2023
Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy.
Review in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Diagnostic research in immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis of research evolution, diagnostic focuses, and future priorities.Frontiers in oncology · 2026Pooled it
- Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01).Cancer immunology research · 2026Trial
- A controlled trial comparing dosimetry and radiation pneumonitis between tomotherapy and IMRT in patients with lung or esophageal cancer.Journal of applied clinical medical physics · 2026Trial
- Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.The oncologist · 2025Trial
- Article
- Clinical Outcomes of Neoadjuvant Chemoimmunotherapy Versus Chemoradiation Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.Annals of surgical oncology · 2026Article
- Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- Induction chemotherapy administration increases the risk of radiation pneumonitis in unresectable stage III NSCLC patients undergoing concurrent chemoradiotherapy with immunotherapy.Therapeutic advances in medical oncology · 2026Article
- Neutrophil CD64 index for rapid diagnosis ofFrontiers in microbiology · 2026Article
- Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer.Journal of inflammation research · 2026Review
- Role of thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy: a review of current evidence.Frontiers in immunology · 2026Review
- External validation and updating of NTCP models for radiation pneumonitis: QUANTEC, Appelt, and a local simplified model.Frontiers in oncology · 2026Article
- Clinical and dosimetric risk factors for radiation pneumonitis after proton therapy in lung cancer patients: a retrospective study.Journal of thoracic disease · 2025Article
- Integrating deep learning and multi-omics features in radiation pneumonitis prediction for lung cancer patients using PET/CT.BMC medical imaging · 2025Article
- VPrecision radiation oncology · 2025Article
- The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis.Translational lung cancer research · 2025Article
- Association of SIRT6 Expression With Risk of Pneumonitis Induced by Radiotherapy in Cancer Patients.Molecular carcinogenesis · 2025Article
- Multicenter development of a deep learning radiomics and dosiomics nomogram to predict radiation pneumonia risk in non-small cell lung cancer.Scientific reports · 2025Article
- A Systematic Review of Pneumonitis Following Treatment with Immune Checkpoint Inhibitors and Radiotherapy.Biomedicines · 2025Review
- Predictive significance of the hemoglobin, albumin, lymphocyte, and platelet score for radiation pneumonitis in lung cancer patients: a respective comparative study with dosimetric parameters.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the common complications of radiotherapy, radiation pneumonia (RP) limits the prognosis of patients. Therefore, better identifying the high-risk factors that lead to RP is essential to effectively prevent its occurrence. However, as lung cancer treatment modalities are being replaced and the era of immunotherapy has arrived, literature that reviews the parameters and mode of radiotherapy, chemotherapy drugs, targeted drugs and current hot immune checkpoint inhibitors related to RP is lacking. This paper summarizes the risk factors for radiation pneumonia by retrieving and analysing previously published literature and the results of large clinical trials. The literature primarily included retrospective analyses, including clinical trials in different periods and a part of the literature review. A systematic literature search of Embase, PubMed, Web of Science, and Clinicaltrials.gov was performed for relevant publications up to 6 Dec. 2022. Search keywords include, but are not limited to, "radiation pneumonia", "pneumonia", "risk factors", "immunotherapy", etc. The factors related to RP in this paper include physical parameters of radiotherapy, including V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.